Richard Kefford

Professor

  • 26183 Citations
  • 73 h-Index
1980 …2022
If you made any changes in Pure these will be visible here soon.

Personal profile

Biography

Professor Richard Kefford AM MB BS PhD FRACP is Professor of Cancer Medicine and Head, Department of Clinical Medicine at Macquarie University, Sydney and Co-Director of Research at Melanoma Institute Australia. He is an internationally acclaimed melanoma researcher and a national leader in academic medicine and medical research with a life-long record of commitment and service to Australian medical research, peer review, professional training and mentoring and community education in oncology. He contributed to the mapping and characterisation of the major melanoma susceptibility genes and the development of international guidelines on genetic testing of those at high melanoma risk. He played a pivotal role in the development of life-extending drug treatments now used as standard-of-care for melanoma, including the first-time in human trial of dabrafenib, the pioneering use of dabrafenib and trametinib for patients with brain metastases, and the Phase 1 clinical trial of pembrolizumab.

Fingerprint Fingerprint is based on mining the text of the person's scientific documents to create an index of weighted terms, which defines the key subjects of each individual researcher.

  • 1 Similar Profiles
Melanoma Medicine & Life Sciences
Neoplasms Medicine & Life Sciences
Mutation Medicine & Life Sciences
Survival Medicine & Life Sciences
Therapeutics Medicine & Life Sciences
Neoplasm Metastasis Medicine & Life Sciences
Mitogen-Activated Protein Kinase Kinases Medicine & Life Sciences
Tumor Suppressor Protein p14ARF Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Projects 2014 2022

Centre for Research Excellence in Implementation Science in Oncology (CRE-ISO)

Braithwaite, J., Ward, R., Currow, D., Delaney, G., Kefford, R., Olver, I., Karnon, J., Crowe, P., Liauw, W., Westbrook, J., Meiser, B., Tieman, J., Verspoor, K., Ellis, L., Krishnasamy, M., Ayliff, N., Hawkins, N., Hibbert, P., Farnsworth, R. & Clay-Williams, R.

1/12/1730/11/22

Project: Other

Determinants of response to immune checkpoint inhibitors in melanoma

Rizos, H., Long, G., Menzies, A. M., Yang, J., Carlino, M., Kefford, R., Scolyer, R., MQRES, M., MQRES 3 (International), M. 3. & De St Groth, B. F.

1/01/17 → …

Project: Research

Acquired resistance to PD1 inhibition in melanoma

Rizos, H., Carlino, M., Kefford, R., Zhang, X. D., Menzies, A. M., Long, G., McGuire, H., Yang, J., Scolyer, R. & De St Groth, B. F.

1/01/17 → …

Project: Research

Molecular determinants of risk, progression and treatment response in melanoma

Kefford, R., Thompson, J., Hersey, P., Mann, G., Scolyer, R., Hayward, N. & Long, G.

1/01/16 → …

Project: Research

Research Output 1980 2019

Circulating cytokines predict immune-related toxicity in melanoma patients receiving anti-PD-1 based immunotherapy

Lim, S. Y., Lee, J. H., Nur Gide, T., Menzies, A. M., Guminski, A., Carlino, M. S., Breen, E., Yang, J. Y. H., Ghazanfar, S., Kefford, R. F., Scolyer, R. A., Long, G. V. & Rizos, H., Mar 2019, In : Clinical Cancer Research. 25, 5, p. 1557-1563 7 p.

Research output: Contribution to journalArticleResearchpeer-review

Immunotherapy
Melanoma
Cytokines
Confidence Intervals
Therapeutics

Whole genome sequencing of melanomas in adolescent and young adults reveals distinct mutation landscapes and the potential role of germline variants in disease susceptibility

Wilmott, J. S., Johansson, P. A., Newell, F., Waddell, N., Ferguson, P., Quek, C., Patch, A. M., Nones, K., Shang, P., Pritchard, A. L., Kazakoff, S., Holmes, O., Leonard, C., Wood, S., Xu, Q., Saw, R. P. M., Spillane, A. J., Stretch, J. R., Shannon, K. F., Kefford, R. F. & 7 othersMenzies, A. M., Long, G. V., Thompson, J. F., Pearson, J. V., Mann, G. J., Hayward, N. K. & Scolyer, R. A., 1 Mar 2019, In : International Journal of Cancer. 144, 5, p. 1049-1060 12 p.

Research output: Contribution to journalArticleResearchpeer-review

Disease Susceptibility
Young Adult
Melanoma
Genome
Mutation

Assessing the incremental contribution of common genomic variants to melanoma risk prediction in two population-based studies

Cust, A. E., Drummond, M., Kanetsky, P. A., Australian Melanoma Family Study Investigators, Leeds Case-Control Study Investigators, Goldstein, A. M., Barrett, J. H., MacGregor, S., Law, M. H., Iles, M. M., Bui, M., Hopper, J. L., Brossard, M., Demenais, F., Taylor, J. C., Hoggart, C., Brown, K. M., Landi, M. T., Newton-Bishop, J. A., Mann, G. J. & 1 othersBishop, D. T., Dec 2018, In : Journal of Investigative Dermatology. 138, 12, p. 2617-2624 8 p.

Research output: Contribution to journalArticleResearchpeer-review

Open Access
File
Melanoma
Population
Pigmentation
Logistic Models
Nevus

Association between circulating tumor DNA and pseudoprogression in patients with metastatic melanoma treated with anti–programmed cell death 1 antibodies

Lee, J. H., Long, G. V., Menzies, A. M., Lo, S., Guminski, A., Whitbourne, K., Peranec, M., Scolyer, R., Kefford, R. F., Rizos, H. & Carlino, M. S., 1 May 2018, In : JAMA Oncology. 4, 5, p. 717-721 5 p.

Research output: Contribution to journalArticleResearchpeer-review

Melanoma
Cell Death
Antibodies
DNA
Neoplasms

Baseline tumor size is an independent prognostic factor for overall survival in patients with melanoma treated with pembrolizumab

Joseph, R. W., Elassaiss-Schaap, J., Kefford, R., Hwu, W. J., Wolchok, J. D., Joshua, A. M., Ribas, A., Hodi, F. S., Hamid, O., Robert, C., Daud, A., Dronca, R., Hersey, P., Weber, J. S., Patnaik, A., de Alwis, D. P., Perrone, A., Zhang, J., Kang, S. P., Ebbinghaus, S. & 2 othersAnderson, K. M. & Gangadhar, T. C., 15 Oct 2018, In : Clinical cancer research : an official journal of the American Association for Cancer Research. 24, 20, p. 4960-4967 8 p.

Research output: Contribution to journalArticleResearchpeer-review

Melanoma
Survival
Neoplasms
pembrolizumab
Ligands